Nursing implications of androgen deprivation therapy-associated bone loss.
Men with locally advanced and nonmetastatic prostate cancer are generally treated with androgen deprivation therapy (ADT) to suppress tumor growth. This treatment, however, is associated with decreased bone density and increased fracture risk, which can lead to increased morbidity and mortality. Nurses play a key role in patient education by promoting lifestyle changes such as diet and exercise that can improve bone strength and decrease risk of ADT-associated bone loss. Pharmacologic interventions using bisphosphonates can significantly reduce bone loss and fracture risk in patients with prostate cancer receiving ADT.
Weingard
Kerri K
KK
Urocare Associates, Garden City, NY, USA.
D000726:Androgen Antagonists / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002136:Calcium, Dietary; D004164:Diphosphonates / Q000627:therapeutic use; D005081:Exercise Therapy; D050723:Fractures, Bone / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control; D006293:Health Promotion / Q000458:organization & administration; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008019:Life Style; D008297:Male; D009017:Morbidity; D024802:Nurse's Role; D009730:Nursing Assessment; D010024:Osteoporosis / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control; D010353:Patient Education as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D014807:Vitamin D / Q000627:therapeutic use; D000077211:Zoledronic Acid
D000726:Androgen Antagonists; D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D007093:Imidazoles; D014807:Vitamin D; D000077211:Zoledronic Acid